Genelux

Genelux Corporation is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies for patients suffering from difficult-to-treat cancers. Their primary approach utilizes oncolytic viruses, specifically modified versions of the vaccinia virus, to selectively target and destroy tumor cells while simultaneously stimulating a personalized immune response. Their lead product candidate, Olvi-Vec, has shown promising results in clinical trials, particularly in patients with platinum-resistant/refractory ovarian cancer. Genelux is currently actively recruiting patients for their OnPrime Phase 3 clinical trial for Olvi-Vec in this indication.

Beyond Olvi-Vec, Genelux is also developing V2ACT Immunotherapy, a personalized cancer treatment that combines oncolytic virotherapy and adoptive cell therapy. They have formed a joint venture, V2ACT Therapeutics, LLC, with TVAX Biomedical, Inc. to advance this technology. Additionally, Genelux has licensed their animal health product candidate, V-VET1, to ELIAS Animal Health for the treatment of cancer in non-human animals. With a robust pipeline and a focus on next-generation immunotherapies, Genelux is committed to redefining the immuno-oncology space and improving outcomes for cancer patients.

Genelux is a biopharmaceutical company dedicated to building a pre-eminent immuno-oncology enterprise that tackles serious unmet medical needs. Their mission is to create and deliver immunotherapies that can stimulate personalized immune system responses to fight cancer, individual by individual. This is achieved by developing therapies that expose the full complement of tumor neo-antigens, effectively activating the body's own defenses to combat the disease.

Genelux emphasizes a culture of innovation and collaboration, driven by a commitment to redefine immuno-oncology and improve outcomes for cancer patients. The company fosters a collaborative and supportive environment, attracting highly skilled individuals who are passionate about leveraging their expertise to develop groundbreaking therapies. The company's dedication to patient benefit and its focus on developing cutting-edge science are key aspects of its culture.

Genelux Corporation is committed to fostering a diverse, equitable, and inclusive work environment where all individuals are valued, respected, and have the opportunity to thrive. They are dedicated to creating an environment that reflects the diversity of the communities they serve and believe that a diverse workforce leads to greater innovation, creativity, and problem-solving. They aim to attract, retain, and develop a diverse talent pool, ensuring equal opportunities for all employees.